British Journal of Haematology | Wiley Online Library
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Haematologica
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis - Biology of Blood and Marrow Transplantation
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
British Journal of Haematology | Wiley Online Library
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
BOSTON trial (SVd) Update at ASCO 2020 | Int Myeloma Fn
DREAMM Clinical Trial Program
Relapsed: D + VD Treatment | DARZALEX® IV (daratumumab)
Changes in hemoglobin and IgA levels. BDR: bortezomib, dexamethasone,... | Download Scientific Diagram
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
